CRISPR Gene Editing Market By Offering (Products, Software, Services); By Application (Gene silencing and Engineering (Animal, Plant), Homology-directed repair (HDR), Transient gene silencing or transcriptional repression (CRISPRi), Pooled genome-scale knockout screening, Drug Discovery, Others); By End-User (Biotechnology and Pharmaceutical Companies, Academic and Research Institutions, Others); By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
CRISPR gene editing is a genetic engineering technique that is used for genomes modification of living organisms in molecular biology. The CRISPR gene-editing technique is considered highly significant in medicine and biotechnology as it allows the editing of genomes in vivo with ease, extremely high precision, and is a cheap technique. The CRISPR gene-editing technique is used in the development of agricultural products, food products, new medicines, and genetically modified organisms. This technique can also be used for controlling pests and pathogens. With increasing cases of cancers across the globe, physicians are finding better treatments for this deadly disease. In many cases, gene editing has proven to be successful in providing treatment for cancers arising from somatic mutations. An increasing case of somatic cell cancer across the globe has been a major driving factor responsible for the growth of the CRISPR gene editing market over the past few years. CRISPR gene editing is also used in the treatment of inherited genetic diseases. The development in the field of genome engineering and genome editing with multiple applications in life science and healthcare has proven to be very much impactful for future purposes. Advancement in the field of genome editing has increased the usage of CRISPR-Cas9 system for the diagnosis and assessment of prokaryotes evolutionary analysis. Genome editing technology is basically used for understanding the evolution of bacteria’s. The most important development in CRISPR gene editing is the development of the Cas-9 technique, wherein the main focus is on somatic cell genome editing and aims to speed up the treatment for several genetic disorders.
The Covid-19 pandemic has impacted several lives and the whole healthcare system around the globe. According to the World Health Organization (WHO), the Covid-19 pandemic has affected nearly 2 million individuals in past one year, resulting in tremendous stress on healthcare infrastructure globally. Surveillance of Covid-19 is very much important in order to avoid the transmission of the disease. In the recent outbreak of Covid-19 strains, there were significant problems in the diagnosis of the diseases owing to a large volume of cases that were reported on a daily basis. This is necessitating the need for the development of a sample processing solution that must be quick, reliable, and accurate. The potential outbreak of Covid-19 in the near future can be handled with molecular biology technologies such as CRISPR gene-editing procedures, which is way better and quicker than the traditional diagnostic methodologies. It has been projected by WHO that the COVID-19 pandemic will see multiple applications of gene editing in order to understand the mutation of coronavirus which is responsible for the deadly disease Covid-19. Recent studies by researchers have proven that CRISPR-gene editing-based tests provide more accurate results for Covid-19 as compared to RT-PCR tests. Thus, the pandemic is expected to propel the CRISPR gene editing market.
In terms of revenue, CRISPR gene editing market was valued at US$ 2231.72 Mn in 2020, growing at a CAGR of 19.78% over the forecast period (2021 – 2029). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global CRISPR Gene Editing Market Revenue & Forecast, (US$ Million), 2021 – 2029
By Offering Outlook
Based on offering, products accounted for the highest market share in the CRISPR gene editing market in 2020, whereas services are expected to be the fastest-growing over the forecast period. Gene editing-based products are used in treatment as well as for research work. They are designed to deliver higher editing efficiency across several targets and cell types. The growing market for gene editing products in research work and medicine manufacturing is driving the growth of products category. There has been a drastic rise in the clinical trial landscape of chronic and genetic diseases which is fueling the demand for product’s segment and is helping in the development of the services category too. Many companies are investing huge amounts in the development and research of CRISPR gene editing products which is another factor boosting the market.
Application Outlook
Gene silencing and engineering accounted for the highest market share in the CRISPR gene editing market in 2020. It is the process to silence, suppress, or limit the expressions of certain genes using genetic engineering techniques. Widespread usage of genome editing in many research projects is further anticipated to boost the market growth of gene silencing and engineering. Gene silencing and engineering technology is widely being applied to improve the productivity of CHO cell lines. The CHO cell lines are used to produce therapeutics of biopharmaceuticals or biologics. They are proteins obtained from biological sources by using complex processes of biotechnology such as R-DNA. One such example of biopharmaceuticals therapeutics is Recombinant Human insulin. Thus, with the usage of the gene silencing and gene engineering tool there are rising advancements in the biopharmaceutical market which is driving the global CRISPR gene editing market for genome editing.
Region Outlook
Based on the regions, North America accounted for a significant share in the CRISPR gene editing market in 2020. The North American region is a part of various healthcare research activities as well as it is a commercial base for the development of advanced therapy with multiple trials being conducted for stem cell therapies and gene therapies. This has contributed to the growth of the market in North America, out of which U.S. has contributed for the major market share in this region. Another factor leading which is leading the growth of North America is due to increasing awareness of technological advancements, early adopters of best-in-class treatments and the proximity of market participants operating in this region.
Competitive Landscape
The report provides both, qualitative and quantitative research of CRISPR gene editing market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings, and specification amongst others.
Some of the players operating in the CRISPR gene editing market are Beam Therapeutics, Caribou Biosciences, Inc., Creative Biolabs, CRISPR Therapeutics, Editas Medicine, Eurofins Genomics, GenScript, Horizon Discovery Ltd., Integrated DNA Technologies, Inc., Intellia Therapeutics, Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, OriGene Technologies, Inc., OXGENE, Sangamo Therapeutics, Synthego, Thermo Fisher Scientific, ToolGen, Inc., Vigene Biosciences.
Global CRISPR Gene Editing Market
By Offering
- Product
- Software
- Services
By Application
- Gene silencing and Engineering
- Animal
- Plant
- Homology-directed repair (HDR)
- Transient gene silencing or transcriptional repression (CRISPRi)
- Pooled genome-scale knockout screening
- Drug Discovery
- Others
By End-User
- Biotechnology and Pharmaceutical Companies
- Academic and Research Institutions
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of CRISPR Gene Editing Market
6. Market Synopsis:
CRISPR Gene Editing Market
7. CRISPR Gene Editing Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
CRISPR Gene Editing Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: CRISPR Gene Editing Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on CRISPR Gene Editing Market
8. Global CRISPR Gene Editing Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global
CRISPR Gene Editing Market Revenue (US$ Mn)
8.2. Global
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
8.2.1. Products
8.2.1.1. Definition
8.2.1.2. Market
Estimation and Penetration, 2015 – 2020
8.2.1.3. Market
Forecast, 2021 – 2029
8.2.1.4. Compound
Annual Growth Rate (CAGR)
8.2.1.5. Regional
Bifurcation
8.2.1.5.1. North
America
8.2.1.5.1.1. Market
Estimation, 2015 – 2020
8.2.1.5.1.2. Market
Forecast, 2021 – 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 – 2020
8.2.1.5.2.2. Market
Forecast, 2021 – 2029
8.2.1.5.3. Asia
Pacific
8.2.1.5.3.1. Market
Estimation, 2015 – 2020
8.2.1.5.3.2. Market
Forecast, 2021 – 2029
8.2.1.5.4. Middle
East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 – 2020
8.2.1.5.4.2. Market
Forecast, 2021 – 2029
8.2.1.5.5. Latin
America
8.2.1.5.5.1. Market
Estimation, 2015 – 2020
8.2.1.5.5.2. Market
Forecast, 2021 – 2029
8.2.2. Software
8.2.2.1. Definition
8.2.2.2. Market
Estimation and Penetration, 2015 – 2020
8.2.2.3. Market
Forecast, 2021 – 2029
8.2.2.4. Compound
Annual Growth Rate (CAGR)
8.2.2.5. Regional
Bifurcation
8.2.2.5.1. North
America
8.2.2.5.1.1. Market
Estimation, 2015 – 2020
8.2.2.5.1.2. Market
Forecast, 2021 – 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 – 2020
8.2.2.5.2.2. Market
Forecast, 2021 – 2029
8.2.2.5.3. Asia
Pacific
8.2.2.5.3.1. Market
Estimation, 2015 – 2020
8.2.2.5.3.2. Market
Forecast, 2021 – 2029
8.2.2.5.4. Middle
East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 – 2020
8.2.2.5.4.2. Market
Forecast, 2021 – 2029
8.2.2.5.5. Latin
America
8.2.2.5.5.1. Market
Estimation, 2015 – 2020
8.2.2.5.5.2. Market
Forecast, 2021 – 2029
8.2.3. Services
8.2.3.1. Definition
8.2.3.2. Market
Estimation and Penetration, 2015 – 2020
8.2.3.3. Market
Forecast, 2021 – 2029
8.2.3.4. Compound
Annual Growth Rate (CAGR)
8.2.3.5. Regional
Bifurcation
8.2.3.5.1. North
America
8.2.3.5.1.1. Market
Estimation, 2015 – 2020
8.2.3.5.1.2. Market
Forecast, 2021 – 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 – 2020
8.2.3.5.2.2. Market
Forecast, 2021 – 2029
8.2.3.5.3. Asia
Pacific
8.2.3.5.3.1. Market
Estimation, 2015 – 2020
8.2.3.5.3.2. Market
Forecast, 2021 – 2029
8.2.3.5.4. Middle
East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 – 2020
8.2.3.5.4.2. Market
Forecast, 2021 – 2029
8.2.3.5.5. Latin
America
8.2.3.5.5.1. Market
Estimation, 2015 – 2020
8.2.3.5.5.2. Market
Forecast, 2021 – 2029
8.3. Key Segment
for Channeling Investments
8.3.1. By
Offering
9. Global CRISPR Gene Editing Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
9.2.1. Gene
silencing and Engineering (Definition, Market Estimation and Penetration, 2015
– 2020, Market Estimation (2015 – 2020), Market Forecast (2021 – 2029),
Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America,
Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on
Animal, Plant)
9.2.1.1. Animal
9.2.1.2. Plant
9.2.2. Homology-directed
repair (HDR)
9.2.2.1. Definition
9.2.2.2. Market
Estimation and Penetration, 2015 – 2020
9.2.2.3. Market
Forecast, 2021 – 2029
9.2.2.4. Compound
Annual Growth Rate (CAGR)
9.2.2.5. Regional
Bifurcation
9.2.2.5.1. North
America
9.2.2.5.1.1. Market
Estimation, 2015 – 2020
9.2.2.5.1.2. Market
Forecast, 2021 – 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 – 2020
9.2.2.5.2.2. Market
Forecast, 2021 – 2029
9.2.2.5.3. Asia
Pacific
9.2.2.5.3.1. Market
Estimation, 2015 – 2020
9.2.2.5.3.2. Market
Forecast, 2021 – 2029
9.2.2.5.4. Middle
East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 – 2020
9.2.2.5.4.2. Market
Forecast, 2021 – 2029
9.2.2.5.5. Latin
America
9.2.2.5.5.1. Market
Estimation, 2015 – 2020
9.2.2.5.5.2. Market
Forecast, 2021 – 2029
9.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
9.2.3.1. Definition
9.2.3.2. Market
Estimation and Penetration, 2015 – 2020
9.2.3.3. Market
Forecast, 2021 – 2029
9.2.3.4. Compound
Annual Growth Rate (CAGR)
9.2.3.5. Regional
Bifurcation
9.2.3.5.1. North
America
9.2.3.5.1.1. Market
Estimation, 2015 – 2020
9.2.3.5.1.2. Market
Forecast, 2021 – 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 – 2020
9.2.3.5.2.2. Market
Forecast, 2021 – 2029
9.2.3.5.3. Asia
Pacific
9.2.3.5.3.1. Market
Estimation, 2015 – 2020
9.2.3.5.3.2. Market
Forecast, 2021 – 2029
9.2.3.5.4. Middle
East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 – 2020
9.2.3.5.4.2. Market
Forecast, 2021 – 2029
9.2.3.5.5. Latin
America
9.2.3.5.5.1. Market
Estimation, 2015 – 2020
9.2.3.5.5.2. Market
Forecast, 2021 – 2029
9.2.4. Pooled
genome-scale knockout screening
9.2.4.1. Definition
9.2.4.2. Market
Estimation and Penetration, 2015 – 2020
9.2.4.3. Market
Forecast, 2021 – 2029
9.2.4.4. Compound
Annual Growth Rate (CAGR)
9.2.4.5. Regional
Bifurcation
9.2.4.5.1. North
America
9.2.4.5.1.1. Market
Estimation, 2015 – 2020
9.2.4.5.1.2. Market
Forecast, 2021 – 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 – 2020
9.2.4.5.2.2. Market
Forecast, 2021 – 2029
9.2.4.5.3. Asia
Pacific
9.2.4.5.3.1. Market
Estimation, 2015 – 2020
9.2.4.5.3.2. Market
Forecast, 2021 – 2029
9.2.4.5.4. Middle
East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 – 2020
9.2.4.5.4.2. Market
Forecast, 2021 – 2029
9.2.4.5.5. Latin
America
9.2.4.5.5.1. Market
Estimation, 2015 – 2020
9.2.4.5.5.2. Market
Forecast, 2021 – 2029
9.2.5. Drug
Discovery
9.2.5.1. Definition
9.2.5.2. Market
Estimation and Penetration, 2015 – 2020
9.2.5.3. Market
Forecast, 2021 – 2029
9.2.5.4. Compound
Annual Growth Rate (CAGR)
9.2.5.5. Regional
Bifurcation
9.2.5.5.1. North
America
9.2.5.5.1.1. Market
Estimation, 2015 – 2020
9.2.5.5.1.2. Market
Forecast, 2021 – 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 – 2020
9.2.5.5.2.2. Market
Forecast, 2021 – 2029
9.2.5.5.3. Asia
Pacific
9.2.5.5.3.1. Market
Estimation, 2015 – 2020
9.2.5.5.3.2. Market
Forecast, 2021 – 2029
9.2.5.5.4. Middle
East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 – 2020
9.2.5.5.4.2. Market
Forecast, 2021 – 2029
9.2.5.5.5. Latin
America
9.2.5.5.5.1. Market
Estimation, 2015 – 2020
9.2.5.5.5.2. Market
Forecast, 2021 – 2029
9.2.6. Others
9.2.6.1. Definition
9.2.6.2. Market
Estimation and Penetration, 2015 – 2020
9.2.6.3. Market
Forecast, 2021 – 2029
9.2.6.4. Compound
Annual Growth Rate (CAGR)
9.2.6.5. Regional
Bifurcation
9.2.6.5.1. North
America
9.2.6.5.1.1. Market
Estimation, 2015 – 2020
9.2.6.5.1.2. Market
Forecast, 2021 – 2029
9.2.6.5.2. Europe
9.2.6.5.2.1. Market
Estimation, 2015 – 2020
9.2.6.5.2.2. Market
Forecast, 2021 – 2029
9.2.6.5.3. Asia
Pacific
9.2.6.5.3.1. Market
Estimation, 2015 – 2020
9.2.6.5.3.2. Market
Forecast, 2021 – 2029
9.2.6.5.4. Middle
East and Africa
9.2.6.5.4.1. Market
Estimation, 2015 – 2020
9.2.6.5.4.2. Market
Forecast, 2021 – 2029
9.2.6.5.5. Latin
America
9.2.6.5.5.1. Market
Estimation, 2015 – 2020
9.2.6.5.5.2. Market
Forecast, 2021 – 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Application
10. Global CRISPR Gene Editing Market Analysis and Forecasts,
2021 – 2029
10.1. Overview
10.2. Global
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
10.2.1. Biotechnology
and Pharmaceutical Companies
10.2.1.1. Definition
10.2.1.2. Market
Estimation and Penetration, 2015 – 2020
10.2.1.3. Market
Forecast, 2021 – 2029
10.2.1.4. Compound
Annual Growth Rate (CAGR)
10.2.1.5. Regional
Bifurcation
10.2.1.5.1. North
America
10.2.1.5.1.1. Market
Estimation, 2015 – 2020
10.2.1.5.1.2. Market
Forecast, 2021 – 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 – 2020
10.2.1.5.2.2. Market
Forecast, 2021 – 2029
10.2.1.5.3. Asia
Pacific
10.2.1.5.3.1. Market
Estimation, 2015 – 2020
10.2.1.5.3.2. Market
Forecast, 2021 – 2029
10.2.1.5.4. Middle
East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 – 2020
10.2.1.5.4.2. Market
Forecast, 2021 – 2029
10.2.1.5.5. Latin
America
10.2.1.5.5.1. Market
Estimation, 2015 – 2020
10.2.1.5.5.2. Market
Forecast, 2021 – 2029
10.2.2. Academic
and Research Institutions
10.2.2.1. Definition
10.2.2.2. Market
Estimation and Penetration, 2015 – 2020
10.2.2.3. Market
Forecast, 2021 – 2029
10.2.2.4. Compound
Annual Growth Rate (CAGR)
10.2.2.5. Regional
Bifurcation
10.2.2.5.1. North
America
10.2.2.5.1.1. Market
Estimation, 2015 – 2020
10.2.2.5.1.2. Market
Forecast, 2021 – 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 – 2020
10.2.2.5.2.2. Market
Forecast, 2021 – 2029
10.2.2.5.3. Asia
Pacific
10.2.2.5.3.1. Market
Estimation, 2015 – 2020
10.2.2.5.3.2. Market
Forecast, 2021 – 2029
10.2.2.5.4. Middle
East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 – 2020
10.2.2.5.4.2. Market
Forecast, 2021 – 2029
10.2.2.5.5. Latin
America
10.2.2.5.5.1. Market
Estimation, 2015 – 2020
10.2.2.5.5.2. Market
Forecast, 2021 – 2029
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market
Estimation and Penetration, 2015 – 2020
10.2.3.3. Market
Forecast, 2021 – 2029
10.2.3.4. Compound
Annual Growth Rate (CAGR)
10.2.3.5. Regional
Bifurcation
10.2.3.5.1. North
America
10.2.3.5.1.1. Market
Estimation, 2015 – 2020
10.2.3.5.1.2. Market
Forecast, 2021 – 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 – 2020
10.2.3.5.2.2. Market
Forecast, 2021 – 2029
10.2.3.5.3. Asia
Pacific
10.2.3.5.3.1. Market
Estimation, 2015 – 2020
10.2.3.5.3.2. Market
Forecast, 2021 – 2029
10.2.3.5.4. Middle
East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 – 2020
10.2.3.5.4.2. Market
Forecast, 2021 – 2029
10.2.3.5.5. Latin
America
10.2.3.5.5.1. Market
Estimation, 2015 – 2020
10.2.3.5.5.2. Market
Forecast, 2021 – 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
End-User
11. North America CRISPR Gene Editing Market Analysis and
Forecasts, 2020 - 2028
11.1. Overview
11.1.1. North
America CRISPR Gene Editing Market Revenue (US$ Mn)
11.2. North
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
11.2.1. Products
11.2.2. Software
11.2.3. Services
11.3. North
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
11.3.1. Gene
silencing and Engineering
11.3.1.1. Animal
11.3.1.2. Plant
11.3.2. Homology-directed
repair (HDR)
11.3.3. Transient
gene silencing or transcriptional repression (CRISPRi)
11.3.4. Pooled
genome-scale knockout screening
11.3.5. Drug
Discovery
11.3.6. Others
11.4. North
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
11.4.1. Biotechnology
and Pharmaceutical Companies
11.4.2. Academic
and Research Institutions
11.4.3. Others
11.5. North
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.1.1.1. Products
11.5.1.1.2. Software
11.5.1.1.3. Services
11.5.1.2. U.S
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
11.5.1.2.1. Gene
silencing and Engineering
11.5.1.2.1.1. Animal
11.5.1.2.1.2. Plant
11.5.1.2.2. Homology-directed
repair (HDR)
11.5.1.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
11.5.1.2.4. Pooled
genome-scale knockout screening
11.5.1.2.5. Drug
Discovery
11.5.1.2.6. Others
11.5.1.3. U.S
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.1.3.1. Biotechnology
and Pharmaceutical Companies
11.5.1.3.2. Academic
and Research Institutions
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.2.1.1. Products
11.5.2.1.2. Software
11.5.2.1.3. Services
11.5.2.2. Canada
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
11.5.2.2.1. Gene
silencing and Engineering
11.5.2.2.1.1. Animal
11.5.2.2.1.2. Plant
11.5.2.2.2. Homology-directed
repair (HDR)
11.5.2.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
11.5.2.2.4. Pooled
genome-scale knockout screening
11.5.2.2.5. Drug
Discovery
11.5.2.2.6. Others
11.5.2.3. Canada
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.2.3.1. Biotechnology
and Pharmaceutical Companies
11.5.2.3.2. Academic
and Research Institutions
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
11.5.3.1.1. Products
11.5.3.1.2. Software
11.5.3.1.3. Services
11.5.3.2. Mexico
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
11.5.3.2.1. Gene
silencing and Engineering
11.5.3.2.1.1. Animal
11.5.3.2.1.2. Plant
11.5.3.2.2. Homology-directed
repair (HDR)
11.5.3.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
11.5.3.2.4. Pooled
genome-scale knockout screening
11.5.3.2.5. Drug
Discovery
11.5.3.2.6. Others
11.5.3.3. Mexico
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
11.5.3.3.1. Biotechnology
and Pharmaceutical Companies
11.5.3.3.2. Academic
and Research Institutions
11.5.3.3.3. Others
11.5.4. Rest of
North America
11.5.4.1. Rest
of North America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
11.5.4.1.1. Products
11.5.4.1.2. Software
11.5.4.1.3. Services
11.5.4.2. Rest
of North America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
11.5.4.2.1. Gene
silencing and Engineering
11.5.4.2.1.1. Animal
11.5.4.2.1.2. Plant
11.5.4.2.2. Homology-directed
repair (HDR)
11.5.4.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
11.5.4.2.4. Pooled
genome-scale knockout screening
11.5.4.2.5. Drug
Discovery
11.5.4.2.6. Others
11.5.4.3. Rest
of North America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
11.5.4.3.1. Biotechnology
and Pharmaceutical Companies
11.5.4.3.2. Academic
and Research Institutions
11.5.4.3.3. Others
11.6. Key
Segment for Channeling Investments
11.6.1. By
Country
11.6.2. By
Offering
11.6.3. By
Application
11.6.4. By
End-User
12. Europe CRISPR Gene Editing Market Analysis and Forecasts,
2020 - 2028
12.1. Overview
12.1.1. Europe
CRISPR Gene Editing Market Revenue (US$ Mn)
12.2. Europe
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.2.1. Products
12.2.2. Software
12.2.3. Services
12.3. Europe
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.3.1. Gene
silencing and Engineering
12.3.1.1. Animal
12.3.1.2. Plant
12.3.2. Homology-directed
repair (HDR)
12.3.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.3.4. Pooled
genome-scale knockout screening
12.3.5. Drug
Discovery
12.3.6. Others
12.4. Europe
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.4.1. Biotechnology
and Pharmaceutical Companies
12.4.2. Academic
and Research Institutions
12.4.3. Others
12.5. Europe
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.1.1.1. Products
12.5.1.1.2. Software
12.5.1.1.3. Services
12.5.1.2. France
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.1.2.1. Gene
silencing and Engineering
12.5.1.2.1.1. Animal
12.5.1.2.1.2. Plant
12.5.1.2.2. Homology-directed
repair (HDR)
12.5.1.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.1.2.4. Pooled
genome-scale knockout screening
12.5.1.2.5. Drug
Discovery
12.5.1.2.6. Others
12.5.1.3. France
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.1.3.1. Biotechnology
and Pharmaceutical Companies
12.5.1.3.2. Academic
and Research Institutions
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The
UK CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.2.1.1. Products
12.5.2.1.2. Software
12.5.2.1.3. Services
12.5.2.2. The
UK CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.2.2.1. Gene
silencing and Engineering
12.5.2.2.1.1. Animal
12.5.2.2.1.2. Plant
12.5.2.2.2. Homology-directed
repair (HDR)
12.5.2.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.2.2.4. Pooled
genome-scale knockout screening
12.5.2.2.5. Drug
Discovery
12.5.2.2.6. Others
12.5.2.3. The
UK CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.2.3.1. Biotechnology
and Pharmaceutical Companies
12.5.2.3.2. Academic
and Research Institutions
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.3.1.1. Products
12.5.3.1.2. Software
12.5.3.1.3. Services
12.5.3.2. Spain
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.3.2.1. Gene
silencing and Engineering
12.5.3.2.1.1. Animal
12.5.3.2.1.2. Plant
12.5.3.2.2. Homology-directed
repair (HDR)
12.5.3.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.3.2.4. Pooled
genome-scale knockout screening
12.5.3.2.5. Drug
Discovery
12.5.3.2.6. Others
12.5.3.3. Spain
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.3.3.1. Biotechnology
and Pharmaceutical Companies
12.5.3.3.2. Academic
and Research Institutions
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.4.1.1. Products
12.5.4.1.2. Software
12.5.4.1.3. Services
12.5.4.2. Germany
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.4.2.1. Gene
silencing and Engineering
12.5.4.2.1.1. Animal
12.5.4.2.1.2. Plant
12.5.4.2.2. Homology-directed
repair (HDR)
12.5.4.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.4.2.4. Pooled
genome-scale knockout screening
12.5.4.2.5. Drug
Discovery
12.5.4.2.6. Others
12.5.4.3. Germany
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.4.3.1. Biotechnology
and Pharmaceutical Companies
12.5.4.3.2. Academic
and Research Institutions
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.5.1.1. Products
12.5.5.1.2. Software
12.5.5.1.3. Services
12.5.5.2. Italy
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.5.2.1. Gene
silencing and Engineering
12.5.5.2.1.1. Animal
12.5.5.2.1.2. Plant
12.5.5.2.2. Homology-directed
repair (HDR)
12.5.5.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.5.2.4. Pooled
genome-scale knockout screening
12.5.5.2.5. Drug
Discovery
12.5.5.2.6. Others
12.5.5.3. Italy
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.5.3.1. Biotechnology
and Pharmaceutical Companies
12.5.5.3.2. Academic
and Research Institutions
12.5.5.3.3. Others
12.5.6. Nordic
Countries
12.5.6.1. Nordic
Countries CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.6.1.1. Products
12.5.6.1.2. Software
12.5.6.1.3. Services
12.5.6.2. Nordic
Countries CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.6.2.1. Gene
silencing and Engineering
12.5.6.2.1.1. Animal
12.5.6.2.1.2. Plant
12.5.6.2.2. Homology-directed
repair (HDR)
12.5.6.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.6.2.4. Pooled
genome-scale knockout screening
12.5.6.2.5. Drug
Discovery
12.5.6.2.6. Others
12.5.6.3. Nordic
Countries CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.6.3.1. Biotechnology
and Pharmaceutical Companies
12.5.6.3.2. Academic
and Research Institutions
12.5.6.3.3. Others
12.5.6.4. Nordic
Countries CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux
Union
12.5.7.1. Benelux
Union CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
12.5.7.1.1. Products
12.5.7.1.2. Software
12.5.7.1.3. Services
12.5.7.2. Benelux
Union CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
12.5.7.2.1. Gene
silencing and Engineering
12.5.7.2.1.1. Animal
12.5.7.2.1.2. Plant
12.5.7.2.2. Homology-directed
repair (HDR)
12.5.7.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.7.2.4. Pooled
genome-scale knockout screening
12.5.7.2.5. Drug
Discovery
12.5.7.2.6. Others
12.5.7.3. Benelux
Union CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
12.5.7.3.1. Biotechnology
and Pharmaceutical Companies
12.5.7.3.2. Academic
and Research Institutions
12.5.7.3.3. Others
12.5.7.4. Benelux
Union CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The
Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of
Europe
12.5.8.1. Rest
of Europe CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
12.5.8.1.1. Products
12.5.8.1.2. Software
12.5.8.1.3. Services
12.5.8.2. Rest
of Europe CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
12.5.8.2.1. Gene
silencing and Engineering
12.5.8.2.1.1. Animal
12.5.8.2.1.2. Plant
12.5.8.2.2. Homology-directed
repair (HDR)
12.5.8.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
12.5.8.2.4. Pooled
genome-scale knockout screening
12.5.8.2.5. Drug
Discovery
12.5.8.2.6. Others
12.5.8.3. Rest
of Europe CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
12.5.8.3.1. Biotechnology
and Pharmaceutical Companies
12.5.8.3.2. Academic
and Research Institutions
12.5.8.3.3. Others
12.6. Key
Segment for Channeling Investments
12.6.1. By
Country
12.6.2. By
Offering
12.6.3. By
Application
12.6.4. By
End-User
13. Asia Pacific CRISPR Gene Editing Market Analysis and
Forecasts, 2020 - 2028
13.1. Overview
13.1.1. Asia
Pacific CRISPR Gene Editing Market Revenue (US$ Mn)
13.2. Asia
Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.2.1. Products
13.2.2. Software
13.2.3. Services
13.3. Asia
Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
13.3.1. Gene
silencing and Engineering
13.3.1.1. Animal
13.3.1.2. Plant
13.3.2. Homology-directed
repair (HDR)
13.3.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.3.4. Pooled
genome-scale knockout screening
13.3.5. Drug
Discovery
13.3.6. Others
13.4. Asia Pacific
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.4.1. Biotechnology
and Pharmaceutical Companies
13.4.2. Academic
and Research Institutions
13.4.3. Others
13.5. Asia
Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.1.1.1. Products
13.5.1.1.2. Software
13.5.1.1.3. Services
13.5.1.2. China
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.1.2.1. Gene
silencing and Engineering
13.5.1.2.1.1. Animal
13.5.1.2.1.2. Plant
13.5.1.2.2. Homology-directed
repair (HDR)
13.5.1.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.1.2.4. Pooled
genome-scale knockout screening
13.5.1.2.5. Drug
Discovery
13.5.1.2.6. Others
13.5.1.3. China
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.1.3.1. Biotechnology
and Pharmaceutical Companies
13.5.1.3.2. Academic
and Research Institutions
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.2.1.1. Products
13.5.2.1.2. Software
13.5.2.1.3. Services
13.5.2.2. Japan
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.2.2.1. Gene
silencing and Engineering
13.5.2.2.1.1. Animal
13.5.2.2.1.2. Plant
13.5.2.2.2. Homology-directed
repair (HDR)
13.5.2.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.2.2.4. Pooled
genome-scale knockout screening
13.5.2.2.5. Drug
Discovery
13.5.2.2.6. Others
13.5.2.3. Japan
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.2.3.1. Biotechnology
and Pharmaceutical Companies
13.5.2.3.2. Academic
and Research Institutions
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.3.1.1. Products
13.5.3.1.2. Software
13.5.3.1.3. Services
13.5.3.2. India
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.3.2.1. Gene
silencing and Engineering
13.5.3.2.1.1. Animal
13.5.3.2.1.2. Plant
13.5.3.2.2. Homology-directed
repair (HDR)
13.5.3.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.3.2.4. Pooled
genome-scale knockout screening
13.5.3.2.5. Drug
Discovery
13.5.3.2.6. Others
13.5.3.3. India
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.3.3.1. Biotechnology
and Pharmaceutical Companies
13.5.3.3.2. Academic
and Research Institutions
13.5.3.3.3. Others
13.5.4. New
Zealand
13.5.4.1. New
Zealand CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.4.1.1. Products
13.5.4.1.2. Software
13.5.4.1.3. Services
13.5.4.2. New
Zealand CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.4.2.1. Gene
silencing and Engineering
13.5.4.2.1.1. Animal
13.5.4.2.1.2. Plant
13.5.4.2.2. Homology-directed
repair (HDR)
13.5.4.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.4.2.4. Pooled
genome-scale knockout screening
13.5.4.2.5. Drug
Discovery
13.5.4.2.6. Others
13.5.4.3. New
Zealand CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.4.3.1. Biotechnology
and Pharmaceutical Companies
13.5.4.3.2. Academic
and Research Institutions
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.5.1.1. Products
13.5.5.1.2. Software
13.5.5.1.3. Services
13.5.5.2. Australia
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.5.2.1. Gene
silencing and Engineering
13.5.5.2.1.1. Animal
13.5.5.2.1.2. Plant
13.5.5.2.2. Homology-directed
repair (HDR)
13.5.5.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.5.2.4. Pooled
genome-scale knockout screening
13.5.5.2.5. Drug
Discovery
13.5.5.2.6. Others
13.5.5.3. Australia
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.5.3.1. Biotechnology
and Pharmaceutical Companies
13.5.5.3.2. Academic
and Research Institutions
13.5.5.3.3. Others
13.5.6. South
Korea
13.5.6.1. South
Korea CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.6.1.1. Products
13.5.6.1.2. Software
13.5.6.1.3. Services
13.5.6.2. South
Korea CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.6.2.1. Gene
silencing and Engineering
13.5.6.2.1.1. Animal
13.5.6.2.1.2. Plant
13.5.6.2.2. Homology-directed
repair (HDR)
13.5.6.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.6.2.4. Pooled
genome-scale knockout screening
13.5.6.2.5. Drug
Discovery
13.5.6.2.6. Others
13.5.6.3. South
Korea CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.6.3.1. Biotechnology
and Pharmaceutical Companies
13.5.6.3.2. Academic
and Research Institutions
13.5.6.3.3. Others
13.5.7. Southeast
Asia
13.5.7.1. Southeast
Asia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
13.5.7.1.1. Products
13.5.7.1.2. Software
13.5.7.1.3. Services
13.5.7.2. Southeast
Asia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
13.5.7.2.1. Gene
silencing and Engineering
13.5.7.2.1.1. Animal
13.5.7.2.1.2. Plant
13.5.7.2.2. Homology-directed
repair (HDR)
13.5.7.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.7.2.4. Pooled
genome-scale knockout screening
13.5.7.2.5. Drug
Discovery
13.5.7.2.6. Others
13.5.7.3. Southeast
Asia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
13.5.7.3.1. Biotechnology
and Pharmaceutical Companies
13.5.7.3.2. Academic
and Research Institutions
13.5.7.3.3. Others
13.5.7.4. Southeast
Asia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest
of Southeast Asia
13.5.8. Rest of
Asia Pacific
13.5.8.1. Rest
of Asia Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
13.5.8.1.1. Products
13.5.8.1.2. Software
13.5.8.1.3. Services
13.5.8.2. Rest
of Asia Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
13.5.8.2.1. Gene
silencing and Engineering
13.5.8.2.1.1. Animal
13.5.8.2.1.2. Plant
13.5.8.2.2. Homology-directed
repair (HDR)
13.5.8.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
13.5.8.2.4. Pooled
genome-scale knockout screening
13.5.8.2.5. Drug
Discovery
13.5.8.2.6. Others
13.5.8.3. Rest
of Asia Pacific CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
13.5.8.3.1. Biotechnology
and Pharmaceutical Companies
13.5.8.3.2. Academic
and Research Institutions
13.5.8.3.3. Others
13.6. Key
Segment for Channeling Investments
13.6.1. By
Country
13.6.2. By
Offering
13.6.3. By
Application
13.6.4. By
End-User
14. Middle East and Africa CRISPR Gene Editing Market Analysis
and Forecasts, 2020 - 2028
14.1. Overview
14.1.1. Middle
East and Africa CRISPR Gene Editing Market Revenue (US$ Mn)
14.2. Middle
East and Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
14.2.1. Products
14.2.2. Software
14.2.3. Services
14.3. Middle
East and Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
14.3.1. Gene
silencing and Engineering
14.3.1.1. Animal
14.3.1.2. Plant
14.3.2. Homology-directed
repair (HDR)
14.3.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.3.4. Pooled
genome-scale knockout screening
14.3.5. Drug
Discovery
14.3.6. Others
14.4. Middle
East and Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
14.4.1. Biotechnology
and Pharmaceutical Companies
14.4.2. Academic
and Research Institutions
14.4.3. Others
14.5. Middle
East and Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Country
14.5.1. Saudi
Arabia
14.5.1.1. Saudi
Arabia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.1.1.1. Products
14.5.1.1.2. Software
14.5.1.1.3. Services
14.5.1.2. Saudi
Arabia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.1.2.1. Gene
silencing and Engineering
14.5.1.2.1.1. Animal
14.5.1.2.1.2. Plant
14.5.1.2.2. Homology-directed
repair (HDR)
14.5.1.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.1.2.4. Pooled
genome-scale knockout screening
14.5.1.2.5. Drug
Discovery
14.5.1.2.6. Others
14.5.1.3. Saudi
Arabia CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.1.3.1. Biotechnology
and Pharmaceutical Companies
14.5.1.3.2. Academic
and Research Institutions
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.2.1.1. Products
14.5.2.1.2. Software
14.5.2.1.3. Services
14.5.2.2. UAE
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
14.5.2.2.1. Gene
silencing and Engineering
14.5.2.2.1.1. Animal
14.5.2.2.1.2. Plant
14.5.2.2.2. Homology-directed
repair (HDR)
14.5.2.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.2.2.4. Pooled
genome-scale knockout screening
14.5.2.2.5. Drug
Discovery
14.5.2.2.6. Others
14.5.2.3. UAE
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.2.3.1. Biotechnology
and Pharmaceutical Companies
14.5.2.3.2. Academic
and Research Institutions
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.3.1.1. Products
14.5.3.1.2. Software
14.5.3.1.3. Services
14.5.3.2. Egypt
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
14.5.3.2.1. Gene
silencing and Engineering
14.5.3.2.1.1. Animal
14.5.3.2.1.2. Plant
14.5.3.2.2. Homology-directed
repair (HDR)
14.5.3.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.3.2.4. Pooled
genome-scale knockout screening
14.5.3.2.5. Drug
Discovery
14.5.3.2.6. Others
14.5.3.3. Egypt
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.3.3.1. Biotechnology
and Pharmaceutical Companies
14.5.3.3.2. Academic
and Research Institutions
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.4.1.1. Products
14.5.4.1.2. Software
14.5.4.1.3. Services
14.5.4.2. Kuwait
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
14.5.4.2.1. Gene
silencing and Engineering
14.5.4.2.1.1. Animal
14.5.4.2.1.2. Plant
14.5.4.2.2. Homology-directed
repair (HDR)
14.5.4.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.4.2.4. Pooled
genome-scale knockout screening
14.5.4.2.5. Drug
Discovery
14.5.4.2.6. Others
14.5.4.3. Kuwait
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.4.3.1. Biotechnology
and Pharmaceutical Companies
14.5.4.3.2. Academic
and Research Institutions
14.5.4.3.3. Others
14.5.5. South
Africa
14.5.5.1. South
Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
14.5.5.1.1. Products
14.5.5.1.2. Software
14.5.5.1.3. Services
14.5.5.2. South
Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
14.5.5.2.1. Gene
silencing and Engineering
14.5.5.2.1.1. Animal
14.5.5.2.1.2. Plant
14.5.5.2.2. Homology-directed
repair (HDR)
14.5.5.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.5.2.4. Pooled
genome-scale knockout screening
14.5.5.2.5. Drug
Discovery
14.5.5.2.6. Others
14.5.5.3. South
Africa CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
14.5.5.3.1. Biotechnology
and Pharmaceutical Companies
14.5.5.3.2. Academic
and Research Institutions
14.5.5.3.3. Others
14.5.6. Rest of
Middle East & Africa
14.5.6.1. Rest
of Middle East & Africa CRISPR Gene Editing Market Revenue (US$ Mn) and
Forecasts, By Offering
14.5.6.1.1. Products
14.5.6.1.2. Software
14.5.6.1.3. Services
14.5.6.2. Rest
of Middle East & Africa CRISPR Gene Editing Market Revenue (US$ Mn) and
Forecasts, By Application
14.5.6.2.1. Gene
silencing and Engineering
14.5.6.2.1.1. Animal
14.5.6.2.1.2. Plant
14.5.6.2.2. Homology-directed
repair (HDR)
14.5.6.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
14.5.6.2.4. Pooled
genome-scale knockout screening
14.5.6.2.5. Drug
Discovery
14.5.6.2.6. Others
14.5.6.3. Rest
of Middle East & Africa CRISPR Gene Editing Market Revenue (US$ Mn) and
Forecasts, By End-User
14.5.6.3.1. Biotechnology
and Pharmaceutical Companies
14.5.6.3.2. Academic
and Research Institutions
14.5.6.3.3. Others
14.6. Key
Segment for Channeling Investments
14.6.1. By
Country
14.6.2. By
Offering
14.6.3. By
Application
14.6.4. By
End-User
15. Latin America CRISPR Gene Editing Market Analysis and
Forecasts, 2020 - 2028
15.1. Overview
15.1.1. Latin
America CRISPR Gene Editing Market Revenue (US$ Mn)
15.2. Latin
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
15.2.1. Products
15.2.2. Software
15.2.3. Services
15.3. Latin America
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
15.3.1. Gene
silencing and Engineering
15.3.1.1. Animal
15.3.1.2. Plant
15.3.2. Homology-directed
repair (HDR)
15.3.3. Transient
gene silencing or transcriptional repression (CRISPRi)
15.3.4. Pooled
genome-scale knockout screening
15.3.5. Drug
Discovery
15.3.6. Others
15.4. Latin
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
15.4.1. Biotechnology
and Pharmaceutical Companies
15.4.2. Academic
and Research Institutions
15.4.3. Others
15.5. Latin
America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.1.1.1. Products
15.5.1.1.2. Software
15.5.1.1.3. Services
15.5.1.2. Brazil
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
15.5.1.2.1. Gene
silencing and Engineering
15.5.1.2.1.1. Animal
15.5.1.2.1.2. Plant
15.5.1.2.2. Homology-directed
repair (HDR)
15.5.1.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
15.5.1.2.4. Pooled
genome-scale knockout screening
15.5.1.2.5. Drug
Discovery
15.5.1.2.6. Others
15.5.1.3. Brazil
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.1.3.1. Biotechnology
and Pharmaceutical Companies
15.5.1.3.2. Academic
and Research Institutions
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Offering
15.5.2.1.1. Products
15.5.2.1.2. Software
15.5.2.1.3. Services
15.5.2.2. Argentina
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By Application
15.5.2.2.1. Gene
silencing and Engineering
15.5.2.2.1.1. Animal
15.5.2.2.1.2. Plant
15.5.2.2.2. Homology-directed
repair (HDR)
15.5.2.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
15.5.2.2.4. Pooled
genome-scale knockout screening
15.5.2.2.5. Drug
Discovery
15.5.2.2.6. Others
15.5.2.3. Argentina
CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By End-User
15.5.2.3.1. Biotechnology
and Pharmaceutical Companies
15.5.2.3.2. Academic
and Research Institutions
15.5.2.3.3. Others
15.5.3. Rest of
Latin America
15.5.3.1. Rest
of Latin America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Offering
15.5.3.1.1. Products
15.5.3.1.2. Software
15.5.3.1.3. Services
15.5.3.2. Rest
of Latin America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
Application
15.5.3.2.1. Gene
silencing and Engineering
15.5.3.2.1.1. Animal
15.5.3.2.1.2. Plant
15.5.3.2.2. Homology-directed
repair (HDR)
15.5.3.2.3. Transient
gene silencing or transcriptional repression (CRISPRi)
15.5.3.2.4. Pooled
genome-scale knockout screening
15.5.3.2.5. Drug
Discovery
15.5.3.2.6. Others
15.5.3.3. Rest
of Latin America CRISPR Gene Editing Market Revenue (US$ Mn) and Forecasts, By
End-User
15.5.3.3.1. Biotechnology
and Pharmaceutical Companies
15.5.3.3.2. Academic
and Research Institutions
15.5.3.3.3. Others
15.6. Key
Segment for Channeling Investments
15.6.1. By
Country
15.6.2. By
Offering
15.6.3. By
Application
15.6.4. By
End-User
16. Competitive Benchmarking
16.1. Market
Share Analysis, 2019
16.2. Global
Presence and Growth Strategies
16.2.1. Mergers
and Acquisitions
16.2.2. Product
Launches
16.2.3. Investments
Trends
16.2.4. R&D
Initiatives
17. Player Profiles
17.1. Beam Therapeutics
17.1.1. Company
Details
17.1.2. Company
Overview
17.1.3. Product
Offerings
17.1.4. Key
Developments
17.1.5. Financial
Analysis
17.1.6. SWOT
Analysis
17.1.7. Business
Strategies
17.2. Caribou
Biosciences, Inc.
17.2.1. Company
Details
17.2.2. Company
Overview
17.2.3. Product
Offerings
17.2.4. Key
Developments
17.2.5. Financial
Analysis
17.2.6. SWOT
Analysis
17.2.7. Business
Strategies
17.3. Creative
Biolabs
17.3.1. Company
Details
17.3.2. Company
Overview
17.3.3. Product
Offerings
17.3.4. Key
Developments
17.3.5. Financial
Analysis
17.3.6. SWOT
Analysis
17.3.7. Business
Strategies
17.4. CRISPR
Therapeutics
17.4.1. Company
Details
17.4.2. Company
Overview
17.4.3. Product
Offerings
17.4.4. Key
Developments
17.4.5. Financial
Analysis
17.4.6. SWOT
Analysis
17.4.7. Business
Strategies
17.5. Editas
Medicine
17.5.1. Company
Details
17.5.2. Company
Overview
17.5.3. Product
Offerings
17.5.4. Key
Developments
17.5.5. Financial
Analysis
17.5.6. SWOT
Analysis
17.5.7. Business
Strategies
17.6. Eurofins
Genomics
17.6.1. Company
Details
17.6.2. Company
Overview
17.6.3. Product
Offerings
17.6.4. Key Developments
17.6.5. Financial
Analysis
17.6.6. SWOT
Analysis
17.6.7. Business
Strategies
17.7. GenScript
17.7.1. Company
Details
17.7.2. Company
Overview
17.7.3. Product
Offerings
17.7.4. Key
Developments
17.7.5. Financial
Analysis
17.7.6. SWOT
Analysis
17.7.7. Business
Strategies
17.8. Horizon
Discovery Ltd
17.8.1. Company
Details
17.8.2. Company
Overview
17.8.3. Product
Offerings
17.8.4. Key
Developments
17.8.5. Financial
Analysis
17.8.6. SWOT
Analysis
17.8.7. Business
Strategies
17.9. Integrated
DNA Technologies, Inc.
17.9.1. Company
Details
17.9.2. Company
Overview
17.9.3. Product
Offerings
17.9.4. Key
Developments
17.9.5. Financial
Analysis
17.9.6. SWOT
Analysis
17.9.7. Business
Strategies
17.10. Intellia
Therapeutics, Inc.
17.10.1. Company
Details
17.10.2. Company
Overview
17.10.3. Product
Offerings
17.10.4. Key
Developments
17.10.5. Financial
Analysis
17.10.6. SWOT
Analysis
17.10.7. Business
Strategies
17.11. Lonza
Group Ltd.
17.11.1. Company
Details
17.11.2. Company
Overview
17.11.3. Product
Offerings
17.11.4. Key
Developments
17.11.5. Financial
Analysis
17.11.6. SWOT
Analysis
17.11.7. Business
Strategies
17.12. Merck
KGaA
17.12.1. Company
Details
17.12.2. Company
Overview
17.12.3. Product
Offerings
17.12.4. Key
Developments
17.12.5. Financial
Analysis
17.12.6. SWOT
Analysis
17.12.7. Business
Strategies
17.13. New
England Biolabs
17.13.1. Company
Details
17.13.2. Company
Overview
17.13.3. Product
Offerings
17.13.4. Key
Developments
17.13.5. Financial
Analysis
17.13.6. SWOT
Analysis
17.13.7. Business
Strategies
17.14. OriGene
Technologies, Inc.
17.14.1. Company
Details
17.14.2. Company
Overview
17.14.3. Product
Offerings
17.14.4. Key
Developments
17.14.5. Financial
Analysis
17.14.6. SWOT
Analysis
17.14.7. Business
Strategies
17.15. OXGENE
17.15.1. Company
Details
17.15.2. Company
Overview
17.15.3. Product
Offerings
17.15.4. Key
Developments
17.15.5. Financial
Analysis
17.15.6. SWOT
Analysis
17.15.7. Business
Strategies
17.16. Sangamo
Therapeutics
17.16.1. Company
Details
17.16.2. Company
Overview
17.16.3. Product
Offerings
17.16.4. Key
Developments
17.16.5. Financial
Analysis
17.16.6. SWOT
Analysis
17.16.7. Business
Strategies
17.17. Synthego
17.17.1. Company
Details
17.17.2. Company
Overview
17.17.3. Product
Offerings
17.17.4. Key
Developments
17.17.5. Financial
Analysis
17.17.6. SWOT
Analysis
17.17.7. Business
Strategies
17.18. Thermo
Fisher Scientific
17.18.1. Company
Details
17.18.2. Company
Overview
17.18.3. Product
Offerings
17.18.4. Key
Developments
17.18.5. Financial
Analysis
17.18.6. SWOT
Analysis
17.18.7. Business
Strategies
17.19. ToolGen,
Inc.
17.19.1. Company
Details
17.19.2. Company
Overview
17.19.3. Product
Offerings
17.19.4. Key
Developments
17.19.5. Financial
Analysis
17.19.6. SWOT
Analysis
17.19.7. Business
Strategies
17.20. Vigene
Biosciences
17.20.1. Company
Details
17.20.2. Company
Overview
17.20.3. Product
Offerings
17.20.4. Key
Developments
17.20.5. Financial
Analysis
17.20.6. SWOT
Analysis
17.20.7. Business Strategies
17.21. Other
Market Participants
18. Key Findings
Note: This
ToC is tentative and can be changed according to the research study conducted
during the course of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.